JP2003523764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003523764A5 JP2003523764A5 JP2001562582A JP2001562582A JP2003523764A5 JP 2003523764 A5 JP2003523764 A5 JP 2003523764A5 JP 2001562582 A JP2001562582 A JP 2001562582A JP 2001562582 A JP2001562582 A JP 2001562582A JP 2003523764 A5 JP2003523764 A5 JP 2003523764A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- equation
- heavy chain
- fragment
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 description 9
- 102000004965 antibodies Human genes 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 206010001897 Alzheimer's disease Diseases 0.000 description 2
- 206010057668 Cognitive disease Diseases 0.000 description 2
- 201000010374 Down syndrome Diseases 0.000 description 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000002490 cerebral Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 108010055790 immunoglobulin B Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 a.以下のアミノ酸配列を有する3つの軽鎖相補性決定領域(CDRs):
軽鎖CDR1:
【数1】
または
【数2】
軽鎖CDR2:
【数3】
および、軽鎖CDR3:
【数4】
およびヒト化免疫グロブリン軽鎖由来の軽鎖フレームワーク配列、
ならびに
b.以下のアミノ酸配列を有する3つの重鎖CDRsを含む重鎖:
重鎖CDR1:
【数5】
重鎖CDR2:
【数6】
または
【数7】
および、重鎖CDR3:
【数8】
およびヒト化免疫グロブリン重鎖由来の重鎖フレームワーク配列、を含む
ヒト化抗体またはその断片。
【請求項2】 軽鎖CDR1が
【数9】
であり、重鎖CDR2が
【数10】
である請求項1記載のヒト化抗体またはその断片。
【請求項3】 以下の配列を含むヒト化軽鎖可変領域:
【数11】
[式中:
第2位のXaaはValまたはIleであり;
第7位のXaaはSerまたはThrであり;
第14位のXaaはThrまたはSerであり;
第15位のXaaはLeuまたはProであり;
第30位のXaaはIleまたはValであり;
第50位のXaaはArg、Gln、またはLysであり;
第88位のXaaはValまたはLeuであり;
第105位のXaaはGlnまたはGlyであり;
第108位のXaaはLysまたはArgであり;ならびに、
第109位のXaaはValまたはLeuである]
および以下の配列を含む重鎖可変領域:
【数12】
[式中:
第1位のXaaはGluまたはGlnであり;
第7位のXaaはSerまたはLeuであり;
第46位のXaaはGlu、Val、Asp、またはSerであり;
第63位のXaaはThrまたはSerであり;
第75位のXaaはAla、Ser、Val、またはThrであり;
第76位のXaaはLysまたはArgであり;
第89位のXaaはGluまたはAspであり;ならびに、
第107位のXaaはLeuまたはThrである]
を含む、請求項1 に記載のヒト化抗体またはその断片。
【請求項4】 配列番号9に記載の配列の軽鎖可変領域および配列番号10に記載の重鎖可変領域を有する、請求項1 に記載のヒト化抗体またはその断片。
【請求項5】 配列番号11に記載の配列の軽鎖および配列番号12に記載の配列の重鎖を有する、請求項4に記載のヒト化抗体またはその断片。
【請求項6】 請求項1〜5のいずれかに記載のヒト化抗体の 抗体断片。
【請求項7】 適当な宿主細胞内で発現された場合に、請求項1〜6のいずれかに記載の抗体を産生する、1またはそれ以上のポリ核酸。
【請求項8】 請求項1〜6のいずれかに記載の抗体 を発現するための発現ベクターであって、該抗体または断片をコードするポリヌクレオチド配列を含む発現ベクター。
【請求項9】 請求項1〜6のいずれかに記載のヒト化抗体または断片を発現することができる細胞。
【請求項10】 請求項1〜6のいずれかに記載のヒト化抗体または断片および製薬的に許容される賦形剤を含む医薬組成物。
【請求項11】 ヒト被検体におけるアミロイドプラークの形成または毒性の可溶性Aβ種の作用を阻害し、アミロイドプラークまたは毒性の可溶性Aβ種の作用を減少させ、認識減退を逆転させ、認識減退を予防し、または認識を改善させる方法であって、 ヒト被検体に、請求項1〜6のいずれかに記載のヒト化抗体またはその断片の有効量を投与することを含む方法。
【請求項12】 臨床的または前臨床的なアルツハイマー疾患、ダウン症候群、または臨床的または前臨床的な脳性アミロイド血管障害と診断されたヒト被検体における臨床的または前臨床的なアルツハイマー疾患、ダウン症候群、または臨床的または前臨床的な脳性アミロイド血管障害を治療する方法であって、該ヒト被検体に、請求項1〜6のいずれかに記載のヒト化抗体またはその断片の有効量を投与することを含む方法。
【請求項1】 a.以下のアミノ酸配列を有する3つの軽鎖相補性決定領域(CDRs):
軽鎖CDR1:
【数1】
または
【数2】
軽鎖CDR2:
【数3】
および、軽鎖CDR3:
【数4】
およびヒト化免疫グロブリン軽鎖由来の軽鎖フレームワーク配列、
ならびに
b.以下のアミノ酸配列を有する3つの重鎖CDRsを含む重鎖:
重鎖CDR1:
【数5】
重鎖CDR2:
【数6】
または
【数7】
および、重鎖CDR3:
【数8】
およびヒト化免疫グロブリン重鎖由来の重鎖フレームワーク配列、を含む
ヒト化抗体またはその断片。
【請求項2】 軽鎖CDR1が
【数9】
であり、重鎖CDR2が
【数10】
である請求項1記載のヒト化抗体またはその断片。
【請求項3】 以下の配列を含むヒト化軽鎖可変領域:
【数11】
[式中:
第2位のXaaはValまたはIleであり;
第7位のXaaはSerまたはThrであり;
第14位のXaaはThrまたはSerであり;
第15位のXaaはLeuまたはProであり;
第30位のXaaはIleまたはValであり;
第50位のXaaはArg、Gln、またはLysであり;
第88位のXaaはValまたはLeuであり;
第105位のXaaはGlnまたはGlyであり;
第108位のXaaはLysまたはArgであり;ならびに、
第109位のXaaはValまたはLeuである]
および以下の配列を含む重鎖可変領域:
【数12】
[式中:
第1位のXaaはGluまたはGlnであり;
第7位のXaaはSerまたはLeuであり;
第46位のXaaはGlu、Val、Asp、またはSerであり;
第63位のXaaはThrまたはSerであり;
第75位のXaaはAla、Ser、Val、またはThrであり;
第76位のXaaはLysまたはArgであり;
第89位のXaaはGluまたはAspであり;ならびに、
第107位のXaaはLeuまたはThrである]
を含む、請求項1 に記載のヒト化抗体またはその断片。
【請求項4】 配列番号9に記載の配列の軽鎖可変領域および配列番号10に記載の重鎖可変領域を有する、請求項1 に記載のヒト化抗体またはその断片。
【請求項5】 配列番号11に記載の配列の軽鎖および配列番号12に記載の配列の重鎖を有する、請求項4に記載のヒト化抗体またはその断片。
【請求項6】 請求項1〜5のいずれかに記載のヒト化抗体の 抗体断片。
【請求項7】 適当な宿主細胞内で発現された場合に、請求項1〜6のいずれかに記載の抗体を産生する、1またはそれ以上のポリ核酸。
【請求項8】 請求項1〜6のいずれかに記載の抗体 を発現するための発現ベクターであって、該抗体または断片をコードするポリヌクレオチド配列を含む発現ベクター。
【請求項9】 請求項1〜6のいずれかに記載のヒト化抗体または断片を発現することができる細胞。
【請求項10】 請求項1〜6のいずれかに記載のヒト化抗体または断片および製薬的に許容される賦形剤を含む医薬組成物。
【請求項11】 ヒト被検体におけるアミロイドプラークの形成または毒性の可溶性Aβ種の作用を阻害し、アミロイドプラークまたは毒性の可溶性Aβ種の作用を減少させ、認識減退を逆転させ、認識減退を予防し、または認識を改善させる方法であって、 ヒト被検体に、請求項1〜6のいずれかに記載のヒト化抗体またはその断片の有効量を投与することを含む方法。
【請求項12】 臨床的または前臨床的なアルツハイマー疾患、ダウン症候群、または臨床的または前臨床的な脳性アミロイド血管障害と診断されたヒト被検体における臨床的または前臨床的なアルツハイマー疾患、ダウン症候群、または臨床的または前臨床的な脳性アミロイド血管障害を治療する方法であって、該ヒト被検体に、請求項1〜6のいずれかに記載のヒト化抗体またはその断片の有効量を投与することを含む方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18460100P | 2000-02-24 | 2000-02-24 | |
US60/184,601 | 2000-02-24 | ||
US25449800P | 2000-12-08 | 2000-12-08 | |
US25446500P | 2000-12-08 | 2000-12-08 | |
US60/254,465 | 2000-12-08 | ||
US60/254,498 | 2000-12-08 | ||
PCT/US2001/006191 WO2001062801A2 (en) | 2000-02-24 | 2001-02-26 | Humanized antibodies that sequester amyloid beta peptide |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008240971A Division JP4914412B2 (ja) | 2000-02-24 | 2008-09-19 | Aβペプチドを隔離するヒト化抗体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2003523764A JP2003523764A (ja) | 2003-08-12 |
JP2003523764A5 true JP2003523764A5 (ja) | 2008-04-10 |
JP4738696B2 JP4738696B2 (ja) | 2011-08-03 |
Family
ID=27391859
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001562582A Expired - Lifetime JP4738696B2 (ja) | 2000-02-24 | 2001-02-26 | Aβペプチドを隔離するヒト化抗体 |
JP2008240971A Expired - Lifetime JP4914412B2 (ja) | 2000-02-24 | 2008-09-19 | Aβペプチドを隔離するヒト化抗体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008240971A Expired - Lifetime JP4914412B2 (ja) | 2000-02-24 | 2008-09-19 | Aβペプチドを隔離するヒト化抗体 |
Country Status (32)
Country | Link |
---|---|
US (4) | US7195761B2 (ja) |
EP (4) | EP1481992B1 (ja) |
JP (2) | JP4738696B2 (ja) |
KR (1) | KR100767146B1 (ja) |
CN (3) | CN101670105B (ja) |
AT (1) | ATE279442T1 (ja) |
AU (1) | AU4178601A (ja) |
BR (1) | BRPI0108676B8 (ja) |
CA (1) | CA2400559C (ja) |
CY (1) | CY1118381T1 (ja) |
CZ (2) | CZ2008595A3 (ja) |
DE (2) | DE60106394T3 (ja) |
DK (2) | DK1257584T4 (ja) |
DZ (1) | DZ3295A1 (ja) |
EA (1) | EA006606B1 (ja) |
ES (2) | ES2611427T3 (ja) |
HK (1) | HK1048640B (ja) |
HR (2) | HRP20020693B1 (ja) |
HU (2) | HUP0204074A3 (ja) |
IL (3) | IL151378A0 (ja) |
LT (1) | LT1481992T (ja) |
MX (1) | MXPA02008145A (ja) |
NO (2) | NO329840B1 (ja) |
NZ (1) | NZ520800A (ja) |
PL (2) | PL210157B1 (ja) |
PT (2) | PT1257584E (ja) |
SI (2) | SI1481992T1 (ja) |
SK (2) | SK288711B6 (ja) |
TR (1) | TR200202799T3 (ja) |
UA (1) | UA75881C2 (ja) |
WO (1) | WO2001062801A2 (ja) |
ZA (1) | ZA200206712B (ja) |
Families Citing this family (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2376693C (en) | 1999-06-16 | 2013-09-10 | Boston Biomedical Research Institute | Immunological control of .beta.-amyloid levels in vivo |
IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
WO2002088307A2 (en) * | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
DE60230736D1 (de) * | 2001-04-30 | 2009-02-26 | Lilly Co Eli | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
WO2003000714A2 (en) * | 2001-06-22 | 2003-01-03 | Panacea Pharmaceuticals, Inc. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
EP1420032B2 (en) † | 2001-08-03 | 2015-12-16 | Medical & Biological Laboratories Co., Ltd. | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
EP1519740A4 (en) * | 2001-08-17 | 2005-11-09 | Lilly Co Eli | FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA |
EP1944040B1 (en) * | 2001-08-17 | 2012-08-01 | Washington University | Assay method for Alzheimer's disease |
JP2005500389A (ja) * | 2001-08-17 | 2005-01-06 | イーライ・リリー・アンド・カンパニー | Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用 |
JP2005503789A (ja) * | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Aβ抗体 |
EP1416965B8 (en) * | 2001-08-17 | 2008-02-13 | Washington University | Assay method for alzheimer's disease |
US7179606B2 (en) * | 2001-11-23 | 2007-02-20 | Syn X Pharma, Inc. | IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20050129691A1 (en) * | 2002-04-25 | 2005-06-16 | Eli Lily And Company Patent Division | Method for treating anxiety and mood disorders in older subjects |
WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
FR2846667B1 (fr) * | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
WO2004056318A2 (en) | 2002-12-19 | 2004-07-08 | New York University | Method for treating amyloid disease |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
WO2004069182A2 (en) * | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
DE602004027348D1 (de) | 2003-02-10 | 2010-07-08 | Applied Molecular Evolution | Abeta-bindende moleküle |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP3011971B1 (en) | 2003-06-27 | 2021-07-21 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
KR101139103B1 (ko) * | 2003-09-12 | 2012-07-05 | 아피리스 아게 | 아페레시스 장치 |
US7848543B2 (en) * | 2004-02-05 | 2010-12-07 | Brainlab Ag | Method and system for prediction and management of material and information transport in an organism |
DK1720909T3 (da) * | 2004-02-23 | 2012-01-30 | Lilly Co Eli | Anti-Abeta antistof |
EP1741783A4 (en) * | 2004-04-27 | 2009-05-27 | Chemo Sero Therapeut Res Inst | HUMAN ANTIAMYLOID BETA PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF |
EP1769002A1 (en) * | 2004-07-02 | 2007-04-04 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta) |
US20060024667A1 (en) | 2004-07-29 | 2006-02-02 | Karen Manucharyan | Compositions and methods for Alzheimer's disease |
KR20070073885A (ko) * | 2004-10-05 | 2007-07-10 | 뉴랄랩 리미티드 | 재조합 단백질 생산을 향상시키는 방법 및 조성물 |
US9901413B2 (en) * | 2004-10-15 | 2018-02-27 | Brainlab Ag | Targeted infusion of agents for treatment of ALS |
US9907485B2 (en) * | 2004-10-15 | 2018-03-06 | Brainlab Ag | Targeted immunization and plaque destruction against Alzheimer's disease |
US9924888B2 (en) * | 2004-10-15 | 2018-03-27 | Brainlab Ag | Targeted infusion of agents against parkinson's disease |
US20060257396A1 (en) * | 2004-12-15 | 2006-11-16 | Jacobsen Jack S | Abeta antibodies for use in improving cognition |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
US7625560B2 (en) * | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20090074775A1 (en) * | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
US7906625B2 (en) * | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
SG162806A1 (en) | 2005-06-17 | 2010-07-29 | Elan Pharma Int Ltd | Methods of purifying anti a beta antibodies |
ES2524984T3 (es) * | 2005-11-30 | 2014-12-16 | Abbvie Inc. | Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos |
WO2007064972A2 (en) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
EP2377886A1 (en) | 2005-12-12 | 2011-10-19 | F. Hoffmann-La Roche AG | Antibody glycosylation in the variable region |
KR101591223B1 (ko) * | 2005-12-12 | 2016-02-04 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
EP2177536B1 (en) * | 2006-03-30 | 2014-06-04 | Glaxo Group Limited | Antibodies against amyloid-beta peptide |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
CN101058608B (zh) * | 2006-04-21 | 2011-02-23 | 杜如昱 | 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途 |
ES2661562T3 (es) * | 2006-07-14 | 2018-04-02 | Ac Immune S.A. | Anticuerpo humanizado contra beta amiloide |
EP3988566A1 (en) * | 2006-07-14 | 2022-04-27 | AC Immune SA | Humanized antibody against amyloid beta |
AU2007275467B2 (en) | 2006-07-14 | 2013-12-05 | Ac Immune S.A. | Humanized antibody against amyloid beta |
KR20150002879A (ko) * | 2006-10-02 | 2015-01-07 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
CA2665423A1 (en) | 2006-10-12 | 2008-04-17 | Wyeth | Methods and compositions with reduced opalescence |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008084402A2 (en) | 2007-01-11 | 2008-07-17 | Philipps-Universitaet Marburg | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
AU2008206555B2 (en) | 2007-01-18 | 2013-07-04 | Eli Lilly And Company | Pegylated Abeta Fab |
JP2010518064A (ja) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Adおよび関連状態の治療のためのピペラジン誘導体 |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
ES2533484T3 (es) | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Derivados de tiourea como inhibidores de la glutaminil ciclasa |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
MX2009011127A (es) * | 2007-04-18 | 2010-03-10 | Janssen Alzheimer Immunotherap | Metodo de prevencion y tratamiento de angiopatia amiloide cerebral. |
US9265577B2 (en) | 2007-05-18 | 2016-02-23 | The Johns Hopkins University | Methods and systems for providing planning and dispensation of research and/or treatment for brain disease |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
JP2010528583A (ja) * | 2007-06-11 | 2010-08-26 | エーシー イミューン ソシエテ アノニム | アミロイドβに対するヒト化抗体 |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
RS53793B1 (en) * | 2007-06-12 | 2015-06-30 | Ac Immune S.A. | HUMANIZED ANTIBODIES AGAINST BETA AMYLOID |
EP2197914A1 (en) * | 2007-09-13 | 2010-06-23 | Delenex Therapeutics AG | HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE |
AU2008311365B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Humanized antibody |
RU2604181C2 (ru) | 2007-10-05 | 2016-12-10 | Дженентек, Инк. | Применение антитела против амилоида бета при глазных заболеваниях |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
AU2008322523B2 (en) * | 2007-11-16 | 2013-10-10 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
AU2008343855B2 (en) | 2007-12-21 | 2013-08-15 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
EP2106802A1 (en) | 2008-04-02 | 2009-10-07 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Modified peptides as synthetic vaccines in amyloid-associated disease |
EP2149380A1 (en) * | 2008-07-29 | 2010-02-03 | Medivet Pharma, S.L. | Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction. |
EP2328908A4 (en) | 2008-08-28 | 2012-11-28 | Univ New York State Res Found | TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US8614297B2 (en) * | 2008-12-22 | 2013-12-24 | Hoffmann-La Roche Inc. | Anti-idiotype antibody against an antibody against the amyloid β peptide |
DK2475428T3 (en) | 2009-09-11 | 2015-09-28 | Probiodrug Ag | Heterocyclic derivatives as glutaminylcyklaseinhibitorer |
BR112012014060B8 (pt) | 2009-12-11 | 2021-07-27 | Araclon Biotech Sl | método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda |
CA2791648A1 (en) | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
WO2011149461A1 (en) | 2010-05-27 | 2011-12-01 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
WO2012016173A2 (en) | 2010-07-30 | 2012-02-02 | Ac Immune S.A. | Safe and functional humanized antibodies |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP2012050437A (ja) * | 2011-09-12 | 2012-03-15 | Janssen Alzheimer Immunotherapy | ベータアミロイドペプチドを認識するヒト化抗体 |
HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
US9963511B2 (en) * | 2011-12-22 | 2018-05-08 | Hoffmann-La Roche Inc. | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
AU2013243947A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
JP6110937B2 (ja) | 2012-05-04 | 2017-04-05 | ファイザー・インク | APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
BR112014032913A2 (pt) | 2012-06-29 | 2017-06-27 | Pfizer | novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2 |
US20150353631A1 (en) * | 2012-07-03 | 2015-12-10 | Janssen Alzheimer Immunotherapy | C-terminal and central epitope a-beta antibodies |
WO2014045162A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
JP2016507551A (ja) | 2013-02-13 | 2016-03-10 | ファイザー・インク | ヘテロアリール置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
ES2638850T3 (es) | 2013-02-19 | 2017-10-24 | Pfizer Inc. | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
PL3594240T3 (pl) | 2013-05-20 | 2024-04-02 | F. Hoffmann-La Roche Ag | Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania |
CA3184564A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2 |
CA3174012A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3052495B1 (en) | 2013-10-04 | 2019-06-26 | Pfizer Inc | Novel bicyclic pyridinones as gamma-secretase modulators |
WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
CA2944308A1 (en) | 2014-04-01 | 2015-10-08 | Pfizer Inc. | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
AP2016009493A0 (en) | 2014-04-10 | 2016-10-31 | Pfizer | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
WO2016020786A1 (en) | 2014-08-06 | 2016-02-11 | Pfizer Inc. | Imidazopyridazine compounds |
EP3786182A1 (en) | 2014-11-19 | 2021-03-03 | Axon Neuroscience SE | Humanized tau antibodies in alzheimer's disease |
EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
CN107001473B (zh) | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 抗-运铁蛋白受体抗体及使用方法 |
ES2818806T3 (es) | 2015-02-03 | 2021-04-14 | Pfizer | Novedosas ciclopropabenzofuranil piridopirazindionas |
HUE051898T2 (hu) | 2015-06-17 | 2021-03-29 | Pfizer | Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként |
JP2018522891A (ja) * | 2015-07-21 | 2018-08-16 | バイオアークティック アーベー | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド |
BR112018003489A2 (pt) | 2015-09-24 | 2018-09-25 | Pfizer | n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas |
JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
WO2017075119A1 (en) | 2015-10-28 | 2017-05-04 | The Trustees Of The Univeresity Of Pennsylvania | Intrathecal administration of adeno-associated-viral vectors for gene therapy |
CA3004498A1 (en) | 2015-11-09 | 2017-05-18 | Neil R. Cashman | Amyloid beta epitopes and antibodies thereto |
JP7065516B2 (ja) | 2015-11-09 | 2022-05-12 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータのn末端エピトープおよびそれに対する立体配座選択的抗体 |
CA3004494A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columiba | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto |
CA3015166C (en) | 2016-02-23 | 2021-08-03 | Pfizer Inc. | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
JP7046018B2 (ja) | 2016-07-01 | 2022-04-01 | ファイザー・インク | 神経性疾患および神経変性疾患を処置するための5,7-ジヒドロピロロピリジン誘導体 |
US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
MX2019003489A (es) | 2016-09-27 | 2020-01-23 | Cero Therapeutics Inc | Moleculas del receptor de envolvimiento quimerico. |
US11124562B2 (en) | 2016-10-28 | 2021-09-21 | Washington University | Anti-ApoE antibodies |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
CA3056030A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
AU2018230109B2 (en) | 2017-03-10 | 2022-05-12 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
EP3634978A1 (en) | 2017-06-07 | 2020-04-15 | Adrx, Inc. | Tau aggregation inhibitors |
IL271290B2 (en) | 2017-06-22 | 2023-11-01 | Pfizer | Dihydro-pyrrolo-pyridine derivatives |
US11530257B2 (en) * | 2017-06-29 | 2022-12-20 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies for treatment of amyloid deposition diseases |
EP3574020B1 (en) | 2017-07-18 | 2024-05-15 | The University of British Columbia | Antibodies to amyloid beta |
US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
WO2019036725A2 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | PEPTIDE INHIBITORS OF TAU AGGREGATION |
JP7286658B2 (ja) | 2017-09-26 | 2023-06-05 | セロ・セラピューティクス・インコーポレイテッド | キメラエンガルフメント受容体分子および使用方法 |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2019074840A1 (en) * | 2017-10-09 | 2019-04-18 | Keith Black | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES |
PT3768669T (pt) | 2018-03-23 | 2023-04-24 | Pfizer | Derivados de piperazina azaspiro |
EP3774864A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
WO2019226690A1 (en) * | 2018-05-21 | 2019-11-28 | New York University | Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage |
AU2019354965A1 (en) | 2018-10-04 | 2021-05-06 | University Of Rochester | Improvement of glymphatic delivery by manipulating plasma osmolarity |
CN113227131A (zh) | 2018-12-20 | 2021-08-06 | 豪夫迈·罗氏有限公司 | 经修饰的抗体Fc及其使用方法 |
FR3091999A1 (fr) * | 2019-01-25 | 2020-07-31 | Mexbrain | Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible |
MX2022004311A (es) | 2019-10-15 | 2022-05-10 | Lilly Co Eli | Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. |
AU2021310926A1 (en) | 2020-07-23 | 2023-03-23 | Othair Prothena Limited | Anti-abeta antibodies |
US20240010713A1 (en) | 2021-01-11 | 2024-01-11 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
WO2023150483A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5278049A (en) * | 1986-06-03 | 1994-01-11 | Incyte Pharmaceuticals, Inc. | Recombinant molecule encoding human protease nexin |
FR2608669A1 (fr) | 1986-12-19 | 1988-06-24 | Boussois Sa | Vitrage pret a sa pose et son procede de fabrication et de fixation |
US4933156A (en) | 1987-04-08 | 1990-06-12 | Salutar, Inc. | Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
US5837822A (en) * | 1992-01-27 | 1998-11-17 | Icos Corporation | Humanized antibodies specific for ICAM related protein |
US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
DE69333144T2 (de) * | 1992-10-26 | 2004-05-19 | Elan Pharmaceuticals, Inc., San Francisco | Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids |
CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
WO1995009236A1 (en) * | 1993-09-28 | 1995-04-06 | The General Hospital Corporation | USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE β/A4 AMYLOID-INDUCED MORPHOLOGY |
JPH09511492A (ja) | 1994-02-03 | 1997-11-18 | ザ ピコワー インスティテュート フォア メディカル リサーチ | アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法 |
US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US20020086847A1 (en) | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
AU743827B2 (en) | 1997-04-09 | 2002-02-07 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
US6787319B2 (en) | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
EP0996736A1 (en) | 1997-08-11 | 2000-05-03 | Chiron Corporation | Methods for genetically modifying t cells |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
CN1589903A (zh) | 1998-05-21 | 2005-03-09 | 田纳西州立大学研究基金会 | 用淀粉样蛋白抗体除去淀粉样蛋白的方法 |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2376693C (en) | 1999-06-16 | 2013-09-10 | Boston Biomedical Research Institute | Immunological control of .beta.-amyloid levels in vivo |
AU6524500A (en) | 1999-08-04 | 2001-03-05 | Northwestern University | Amyloid beta protein (globular assembly and uses thereof) |
JP2003509020A (ja) | 1999-09-03 | 2003-03-11 | ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド | プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法 |
US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
US20020009445A1 (en) | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
ES2330082T3 (es) | 2000-09-06 | 2009-12-04 | Aventis Pharma S.A. | Metodos y composicones para enfermedades asociadas con la amiloidosis. |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
EP1416965B8 (en) | 2001-08-17 | 2008-02-13 | Washington University | Assay method for alzheimer's disease |
-
2001
- 2001-02-26 IL IL15137801A patent/IL151378A0/xx unknown
- 2001-02-26 DZ DZ013295A patent/DZ3295A1/fr active
- 2001-02-26 KR KR1020027011027A patent/KR100767146B1/ko active IP Right Grant
- 2001-02-26 EP EP04011466.2A patent/EP1481992B1/en not_active Expired - Lifetime
- 2001-02-26 TR TR2002/02799T patent/TR200202799T3/xx unknown
- 2001-02-26 NZ NZ520800A patent/NZ520800A/en not_active IP Right Cessation
- 2001-02-26 ES ES04011466.2T patent/ES2611427T3/es not_active Expired - Lifetime
- 2001-02-26 WO PCT/US2001/006191 patent/WO2001062801A2/en active Application Filing
- 2001-02-26 CN CN200810214672.7A patent/CN101670105B/zh not_active Expired - Lifetime
- 2001-02-26 EP EP16196667.6A patent/EP3150633A1/en not_active Withdrawn
- 2001-02-26 DE DE60106394T patent/DE60106394T3/de not_active Expired - Lifetime
- 2001-02-26 CN CN201410322976.0A patent/CN104341500A/zh active Pending
- 2001-02-26 PL PL356798A patent/PL210157B1/pl unknown
- 2001-02-26 EA EA200200897A patent/EA006606B1/ru not_active IP Right Cessation
- 2001-02-26 ES ES01913081T patent/ES2184660T5/es not_active Expired - Lifetime
- 2001-02-26 CZ CZ2008-595A patent/CZ2008595A3/cs not_active IP Right Cessation
- 2001-02-26 DK DK01913081.4T patent/DK1257584T4/da active
- 2001-02-26 CA CA2400559A patent/CA2400559C/en not_active Expired - Lifetime
- 2001-02-26 AU AU4178601A patent/AU4178601A/xx active Pending
- 2001-02-26 SI SI200131058A patent/SI1481992T1/sl unknown
- 2001-02-26 PT PT01913081T patent/PT1257584E/pt unknown
- 2001-02-26 JP JP2001562582A patent/JP4738696B2/ja not_active Expired - Lifetime
- 2001-02-26 MX MXPA02008145A patent/MXPA02008145A/es active IP Right Grant
- 2001-02-26 AT AT01913081T patent/ATE279442T1/de active
- 2001-02-26 PL PL386125A patent/PL218883B1/pl unknown
- 2001-02-26 EP EP01913081A patent/EP1257584B2/en not_active Expired - Lifetime
- 2001-02-26 SI SI200130240T patent/SI1257584T2/sl unknown
- 2001-02-26 CZ CZ2002-2851A patent/CZ304211B6/cs not_active IP Right Cessation
- 2001-02-26 HU HU0204074A patent/HUP0204074A3/hu unknown
- 2001-02-26 UA UA2002086888A patent/UA75881C2/uk unknown
- 2001-02-26 EP EP16161726.1A patent/EP3070100B1/en not_active Expired - Lifetime
- 2001-02-26 DE DE1257584T patent/DE1257584T1/de active Pending
- 2001-02-26 PT PT40114662T patent/PT1481992T/pt unknown
- 2001-02-26 DK DK04011466.2T patent/DK1481992T3/en active
- 2001-02-26 CN CN018084303A patent/CN1426423B/zh not_active Expired - Lifetime
- 2001-02-26 SK SK12212002A patent/SK288711B6/sk not_active IP Right Cessation
- 2001-02-26 BR BRPI0108676A patent/BRPI0108676B8/pt not_active IP Right Cessation
- 2001-02-26 LT LTEP04011466.2T patent/LT1481992T/lt unknown
- 2001-02-26 SK SK69-2008A patent/SK288723B6/sk not_active IP Right Cessation
-
2002
- 2002-08-20 NO NO20023957A patent/NO329840B1/no not_active IP Right Cessation
- 2002-08-21 IL IL151378A patent/IL151378A/en active IP Right Grant
- 2002-08-21 ZA ZA200206712A patent/ZA200206712B/en unknown
- 2002-08-21 US US10/226,435 patent/US7195761B2/en not_active Expired - Lifetime
- 2002-08-22 HR HR20020693A patent/HRP20020693B1/xx not_active IP Right Cessation
-
2003
- 2003-01-02 HK HK03100011.2A patent/HK1048640B/zh active IP Right Maintenance
-
2005
- 2005-09-12 US US11/224,623 patent/US20060039906A1/en not_active Abandoned
-
2008
- 2008-02-08 US US12/028,641 patent/US7892545B2/en not_active Expired - Fee Related
- 2008-08-21 IL IL193631A patent/IL193631A/en active IP Right Grant
- 2008-09-03 HR HRP20080430AA patent/HRP20080430B1/hr not_active IP Right Cessation
- 2008-09-04 NO NO20083805A patent/NO337363B1/no not_active IP Right Cessation
- 2008-09-19 JP JP2008240971A patent/JP4914412B2/ja not_active Expired - Lifetime
-
2010
- 2010-12-22 US US12/976,282 patent/US8591894B2/en not_active Expired - Lifetime
-
2011
- 2011-02-26 HU HU0800571A patent/HU230768B1/hu unknown
-
2016
- 2016-12-15 CY CY20161101301T patent/CY1118381T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003523764A5 (ja) | ||
JP7337204B2 (ja) | 単鎖可変フラグメントcd3結合タンパク質 | |
JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
TWI374893B (en) | Humanized antibodies that recognize beta amyloid peptide | |
JP7101621B2 (ja) | 単一ドメイン血清アルブミン結合タンパク質 | |
JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
EP1596809B1 (en) | Abeta binding molecules | |
KR100767146B1 (ko) | Aβ 펩티드를 격리시키는 인간화 항체 | |
JP5047996B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
TWI508741B (zh) | 對抗rgma蛋白質之單株抗體及其用途 | |
TWI734722B (zh) | 使用胃抑肽受體(gipr)結合蛋白與glp-1促效劑之組合來治療或改善代謝病症之方法 | |
TW201525004A (zh) | 結合前蛋白轉化酶枯草桿菌蛋白酶加工酶9型之人類抗原結合蛋白 | |
JP2005503789A5 (ja) | ||
JP2003525061A5 (ja) | ||
JP2008515446A5 (ja) | ||
RU2003107564A (ru) | Антитела к человеческому il-1бета | |
CA2507099A1 (en) | Chimeric and humanized antibodies to .alpha.5.beta.1 integrin that modulate angiogenesis | |
KR20230021773A (ko) | 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도 | |
JP2010522141A (ja) | PEG化AβFAB | |
JP2017507131A5 (ja) | ||
KR102132604B1 (ko) | 비형 간염 표면 항원에 대한 항체 및 그의 용도 | |
JP2023120208A (ja) | 補体成分c5または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 | |
CN110960490A (zh) | 一种抗egfr抗体偶联药物组合物及其用途 | |
CA3161118A1 (en) | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies | |
EP4257603A1 (en) | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |